SIM0270 clinical trials
SIM0270 is named as an intervention in 3 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 1. The lead sponsor is Jiangsu Simcere Pharmaceutical Co., Ltd. The most-studied condition is Healthy Adult Participants.
Patient leaflets for SIM0270
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of SIM0270
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
NCT07357610 · ClinicalTrials.gov ↗ · Healthy Adult Participants
|
Phase 1 | Recruiting | Jiangsu Simcere Pharmaceutical Co., Ltd | China |
|
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921 · Locally Advanced or Metastatic Breast Cancer
|
Phase 3 | Active, closed | Jiangsu Simcere Pharmaceutical Co., Ltd | China |
|
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
NCT05293964 · ClinicalTrials.gov ↗ · Breast Cancer
|
Phase 1 | Active, closed | Jiangsu Simcere Pharmaceutical Co., Ltd | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with SIM0270
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Jiangsu Simcere Pharmaceutical Co., Ltd | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 3 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about SIM0270 trials
How many clinical trials are testing SIM0270?
3 current trials in our China register name SIM0270 (also registered as SCR6852) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are SIM0270 trials recruiting patients?
Yes. 1 of the 3 trials is recruiting: 1 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors SIM0270 clinical trials?
The lead sponsor is Jiangsu Simcere Pharmaceutical Co., Ltd. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SIM0270 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SIM0270 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SIM0270 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.